771 related articles for article (PubMed ID: 26031566)
1. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
6. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
8. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
9. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Broedl UC; Woerle HJ;
Diabetes Care; 2014 Jun; 37(6):1650-9. PubMed ID: 24722494
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
[TBL] [Abstract][Full Text] [Related]
14. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2015 Dec; 14():154. PubMed ID: 26701110
[TBL] [Abstract][Full Text] [Related]
20. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
